Adage Capital Partners Gp, L.L.C. Mirati Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

  • $51 Billion
  • Q1 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024
SELL
$41.99 - $62.38 $21.3 Million - $31.7 Million
-507,576 Reduced 43.2%
667,424 $39.2 Million
Q3 2023

Nov 14, 2023
BUY
$27.8 - $45.35 $32.7 Million - $53.3 Million
1,175,000 New
1,175,000 $51.2 Million
Q3 2022

Nov 14, 2022
BUY
$59.5 - $86.7 $84.4 Million - $123 Million
1,418,747 New
1,418,747 $99.1 Million

Others Institutions Holding MRTX

# of Institutions
19
Shares Held
3.57M
Call Options Held
0
Put Options Held
36.6K
View Full List

About Mirati Therapeutics, Inc.

MRTX Quotes by TradingView
  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Adage Capital Partners Gp, L.L.C. Portfolio

Follow Adage Capital Partners Gp, L.L.C. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email